Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
April 26, 2021 DOI: 10.64239/pi-qt2602 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized controlled trial |
|---|---|
| Population | Patients with major depression |
| Intervention | Psilocybin |
| Topics | Depression Psilocybin |
| Key findings | Psilocybin was superior to a delayed-treatment control group with an effect size over 2. |
Abstract
In patients with major depression, psilocybin was superior to a delayed-treatment control group with an effect size over 2 (relative effect sizes: 0.2 small, 0.5 medium, 1.0 large; antidepressants, on average, are 0.3). Who were these patients? Are they like yours?
Comparable studies
Other randomized controlled trials on psilocybin for depression, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety | 2016 | Randomized controlled trial | n = 51 |
| Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Patients with cancer-related anxiety and depression | 2016 | Double-blind, placebo-controlled, crossover trial | n = 29 |
| Trial of Psilocybin versus Escitalopram for Depression Selected group of patients with depression | 2021 | Randomized controlled trial | |
| Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder Adults aged 21 to 75 years with major depressive disorder, not currently using... | 2020 | Randomized controlled trial | n = 24 |
| Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. Adults with treatment-resistant depression | 2022 | Phase 2 double-blind randomized controlled trial | n = 233 |